Drug Trial Radar · NCT06478719
To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jun 24, 2024
Primary completion
Jun 7, 2028
Study completion Aug 6, 2028
Sponsor
- Lead sponsor
- Febico Biomedical Corp.Industry
- Sponsor type
- Industry
- Collaborators
- National Taiwan University Hospital
- First posted
- Jun 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the efficacy of FB-1603 on improving liver function impairment in hepatocellular carcinoma patients receiving transarterial chemoembolization. The main question it aims to answer is: Changes in the level of liver function parameters, including AST, ALT, or total bilirubin, from baseline to Visit 3, Visit 4, Visit 5, and Visit 6 There is a comparison group: Researchers will compare arm 1 placebo to see if FB-1603 is work to treat the liver function. Participants will 1. Take drug FB-1603 990mg/day, FB-1603 1980mg/day or a placebo every day for 10 weeks. 2. Visit the clinic on day 4, 7, 10, 14, 28, 56 and 84 (follow-up)
Conditions
- Hepatocellular Carcinoma
Interventions
PlaceboDrug
Placebo oral capsule
FB-1603Drug
FB-1603 (165 mg/cap) oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in the level of liver functionTime frame: from baseline (day 0) to Visit 3 (day 4), Visit 4(day 7), Visit 5(day 10), and Visit 6(day 14)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
National Taiwan University Hospital
Taipei, Taiwan, Taiwan · Recruiting
Linkou Chang Gung Memorial Hospital
Taoyuan, Taiwan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.